Search

Author/Creator Dührsen, U.

1. A Comprehensive Analysis of the Cellular and EBV‐Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV‐Associated Tumors. Issue 11 (4th August 2014)

Authors:
Fink, S. E. K.; Gandhi, M. K.; Nourse, J. P.; Keane, C.; Jones, K.; Crooks, P.; Jöhrens, K.; Korfel, A.; Schmidt, H.; Neumann, S.; Tiede, A.; Jäger, U.; Dührsen, U.; Neuhaus, R.; Dreyling, M.; Borchert, K.; Südhoff, T.; Riess, H.; Anagnostopoulos, I.; Trappe, R. U.
Journal:
American journal of transplantation
Issue:
Volume 14:Issue 11(2014:Nov.)
Page Start:
2577
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD‐1 inhibitors. (2nd December 2021)

Authors:
Jansen, P.; Lodde, G.C.; Wetter, A.; Welt, A.; Stuschke, M.; Dührsen, U.; Stoffels, I.; Klode, J.; Livingstone, E.; Zimmer, L.; Roesch, A.; Hadaschik, E.; Griewank, K. G.; Schadendorf, D.; Ugurel, S.
Journal:
Journal of the European Academy of Dermatology and Venereology
Issue:
Volume 36:Number 1(2022)Supplement
Page Start:
41
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial. Issue 4 (3rd March 2015)

Authors:
Trappe, R. U.; Choquet, S.; Dierickx, D.; Mollee, P.; Zaucha, J. M.; Dreyling, M. H.; Dührsen, U.; Tarella, C.; Shpilberg, O.; Sender, M.; Salles, G.; Morschhauser, F.; Jaccard, A.; Lamy, T.; Reinke, P.; Neuhaus, R.; Lehmkuhl, H.; Horst, H. A.; Leithäuser, M.; Schlattmann, P.
Journal:
American journal of transplantation
Issue:
Volume 15:Issue 4(2015:Apr.)
Page Start:
1091
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY ("3 + 7") FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG. (23rd June 2022)

Authors:
Lübbert, M.; Wijermans, P.; Kicinski, M.; Chantepie, S.; van der Velden, W.; Noppeney, R.; Griskevicius, L.; Neubauer, A.; Crysandt, M.; Vrhovac, R.; Luppi, M.; Fuhrmann, S.; Audisio, E.; Candoni, A.; Legrand, O.; Foà, R.; Gaidano, G.; van Lammeren-Venema, D.; Posthuma, E. F.; Hoogendoorn, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
26
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗